Factors predicting biochemical response and survival benefits following radioligand therapy with [177 Lu] Lu-PSMA in metastatic castrate-resistant prostate cancer: a review - Manafi-Farid, R; Harsini, S; Saidi, B (Eur J Nucl Med Mol Imaging, 2021)